Search
for
Sort by
Research 181–210 of 1000+
- Can we teach old drugs new tricks?—Repurposing of neuropharmacological drugs for inflammatory skin diseases
- The ATP sensitive potassium channel (KATP) is a novel target for migraine drug development
- Analysis of Adverse Drug Reactions in Pediatric Patients with Epilepsy: An Intensive Pharmacovigilance Study
- LabeledIn: Cataloging labeled indications for human drugs
- PROTACs: A novel strategy for cancer drug discovery and development
- The Effectiveness of Cerium Oxide Nanoparticle-Based Drugs in Wound Healing in Animal Models
- Progress in Lipid and Inorganic Nanocarriers for Enhanced Skin Drug Delivery
- The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs
- Assessing the cost-effectiveness of DNA origami nanostructures for targeted delivery of anti-cancer drugs to tumours
- The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19
- Recent Insights into the Potential and Challenges of Sericin as a Drug Delivery Platform for Multiple Biomedical Applications
- Hair Care Cosmetics Regulation in Different Countries – A Comparative Study
- Functional characterization of OR51B5 and OR1G1 in human lung epithelial cells as potential drug targets for non-type 2 lung diseases
- Perspective Chapter: Repurposing Natural Products to Target COVID-19 – Molecular Targets and New Avenues for Drug Discovery
- [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing].
- Potential use of the Asteraceae family as a cure for diabetes: A review of ethnopharmacology to modern day drug and nutraceuticals developments
- Comparative Evaluation of Wound Healing Effect of Cord Blood Low Molecular Weight Fraction (Below 5 kDa) and Actovegin Drug in Skin Cryolesions
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche.
- Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems
- Medical Remedies for Alopecia
- Polystyrene-b-poly (acrylic acid) nanovesicles coated by modified chitosans for encapsulation of minoxidil
- The Necessity to Investigate In Vivo Fate of Nanoparticle-Loaded Dissolving Microneedles
- Frontiers in Topical Photoprotection
- Exosomes based advancements for application in medical aesthetics
- Biotechs target stagnant baldness market
- From Plants to Wound Dressing and Transdermal Delivery of Bioactive Compounds
- Chitin and Chitosans: Characteristics, Eco-Friendly Processes, and Applications in Cosmetic Science
- Nanoparticles for Topical Application in the Treatment of Skin Dysfunctions—An Overview of Dermo-Cosmetic and Dermatological Products